Erratum to: Phase II Trial of Neoadjuvant/adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/recurrent Operable Gastrointestinal Stromal Tumors: Long-term Follow-up Results of Radiation Therapy Oncology Group 0132
Erratum to: Ann Surg Oncol (2011) DOI 10.1245/s10434-011-2190-5
In the original article, Fig. 1 contained an error. The bottom left box of the figure should have said “Continued Imatinib 600 mg/day for 24 months” not “Continued Imatinib 600 mg/day for 24 hours.”
The figure is reprinted here correctly.
© Society of Surgical Oncology 2012